Bridget E. Bunner

Array ( [id] => 13444151 [patent_doc_number] => 20180273618 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => Combination Therapy For Treatment Of Disease [patent_app_type] => utility [patent_app_number] => 15/889532 [patent_app_country] => US [patent_app_date] => 2018-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51826 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15889532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16321291 [patent_doc_number] => 10781247 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-22 [patent_title] => Targeted therapeutics based on engineered proteins that bind EGFR [patent_app_type] => utility [patent_app_number] => 15/886118 [patent_app_country] => US [patent_app_date] => 2018-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 17 [patent_no_of_words] => 28889 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15886118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13428059 [patent_doc_number] => 20180265572 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS [patent_app_type] => utility [patent_app_number] => 15/866919 [patent_app_country] => US [patent_app_date] => 2018-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36304 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15866919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13357347 [patent_doc_number] => 20180230213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => ANTI-NOTCH3 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/864710 [patent_app_country] => US [patent_app_date] => 2018-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21730 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15864710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18351481 [patent_doc_number] => 20230139592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => SIRP-GAMMA TARGETED AGENTS FOR USE IN THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/470719 [patent_app_country] => US [patent_app_date] => 2017-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29422 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16470719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12750481 [patent_doc_number] => 20180141994 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => TOLL-LIKE RECEPTOR 2 BINDING EPITOPE AND BINDING MEMBER THERETO [patent_app_type] => utility [patent_app_number] => 15/842044 [patent_app_country] => US [patent_app_date] => 2017-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21496 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15842044 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15666441 [patent_doc_number] => 10597438 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-24 [patent_title] => PD-L1 binding fibronectin type III domains [patent_app_type] => utility [patent_app_number] => 15/840281 [patent_app_country] => US [patent_app_date] => 2017-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16871 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15840281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15726803 [patent_doc_number] => 10611823 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-07 [patent_title] => CD137 binding fibronectin type III domains [patent_app_type] => utility [patent_app_number] => 15/840303 [patent_app_country] => US [patent_app_date] => 2017-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20713 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15840303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14963217 [patent_doc_number] => 20190309086 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-10 [patent_title] => TLR9-BINDING CHIMERIC ANTIGEN RECEPTORS [patent_app_type] => utility [patent_app_number] => 16/467286 [patent_app_country] => US [patent_app_date] => 2017-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33860 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16467286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17704576 [patent_doc_number] => 20220204582 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => SYNTHETIC IMMUNE RECEPTORS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/465668 [patent_app_country] => US [patent_app_date] => 2017-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 125224 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16465668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15590267 [patent_doc_number] => 20200071668 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => EXOSOME FOR STIMULATING T CELL AND PHARMACEUTICAL USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/465919 [patent_app_country] => US [patent_app_date] => 2017-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7706 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16465919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12702295 [patent_doc_number] => 20180125931 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => RECOMBINANT HUMAN CC10 AND COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF NASAL RHINITIS [patent_app_type] => utility [patent_app_number] => 15/809357 [patent_app_country] => US [patent_app_date] => 2017-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9859 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15809357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14778029 [patent_doc_number] => 20190263912 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => MODULATION OF INTESTINAL EPITHELIAL CELL DIFFERENTIATION, MAINTENANCE AND/OR FUNCTION THROUGH T CELL ACTION [patent_app_type] => utility [patent_app_number] => 16/348911 [patent_app_country] => US [patent_app_date] => 2017-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 99508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16348911 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14700141 [patent_doc_number] => 10377804 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-13 [patent_title] => Anti-BAFF antibodies [patent_app_type] => utility [patent_app_number] => 15/803993 [patent_app_country] => US [patent_app_date] => 2017-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 33787 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15803993 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14993841 [patent_doc_number] => 20190315878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => BISPECIFIC ANTIBODIES THAT MODULATE TLR-4 SIGNALING AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/347678 [patent_app_country] => US [patent_app_date] => 2017-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18201 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16347678 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12239943 [patent_doc_number] => 20180072807 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-15 [patent_title] => 'Recombinant TNF Ligand Family Member Polypeptides with Antibody Binding Domain and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 15/797059 [patent_app_country] => US [patent_app_date] => 2017-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 21056 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15797059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12657067 [patent_doc_number] => 20180110855 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-26 [patent_title] => NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/792266 [patent_app_country] => US [patent_app_date] => 2017-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20215 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15792266 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13942415 [patent_doc_number] => 10206952 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-19 [patent_title] => Enhanced reconstitution and autoreconstitution of the hematopoietic compartment [patent_app_type] => utility [patent_app_number] => 15/785000 [patent_app_country] => US [patent_app_date] => 2017-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 89 [patent_no_of_words] => 45061 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15785000 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12158842 [patent_doc_number] => 20180030109 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'TUMOR TARGETED TNF-RELATED APOPTOSIS INDUCING LIGAND FUSION POLYPEPTIDE, METHODS AND USES THEREFOR' [patent_app_type] => utility [patent_app_number] => 15/730441 [patent_app_country] => US [patent_app_date] => 2017-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 10031 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15730441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12624969 [patent_doc_number] => 20180100153 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-12 [patent_title] => Method and kit for use in inhiiting tumor progression, predicting or determining tumor progression state in VGF expressing cancers [patent_app_type] => utility [patent_app_number] => 15/726711 [patent_app_country] => US [patent_app_date] => 2017-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7411 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15726711 [rel_patent_id] =>[rel_patent_doc_number] =>)